Compare TLRY & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLRY | PHAT |
|---|---|---|
| Founded | N/A | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.5M | 590.6M |
| IPO Year | 2018 | 2019 |
| Metric | TLRY | PHAT |
|---|---|---|
| Price | $3.03 | $6.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | $5.89 | ★ $20.09 |
| AVG Volume (30 Days) | ★ 3.6M | 1.2M |
| Earning Date | 10-08-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.69 | 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $20.15 | $80.58 |
| Revenue Next Year | $5.32 | $56.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $0.77 | $6.52 |
| 52 Week High | $15.70 | $18.31 |
| Indicator | TLRY | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 23.02 | 38.36 |
| Support Level | N/A | $6.52 |
| Resistance Level | $4.91 | $9.74 |
| Average True Range (ATR) | 0.18 | 0.37 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 2.58 | 22.50 |
Tilray is as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. The company portfolio includes brand such as Sweet Water Brewing, Montauk Brewing, Brew Dog, Shock Top, 10 Barrell, Breckenridge Brewery, Blue Point Brewing, Breckenridge Distillery, Revolver, Terrapin, Broken Coast, Good Supply, Redecan, Solei, Tilray, ARX, XMG, Manitoba Harvest and Hi-Ball. The company has four segment Beverage, Cannabis, Distribution and Wellness. The majority of the revenue is generated from Distribution business which encompasses the purchase and resale of pharmaceuticals products to customers.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.